Lecigimon

Entacapone, Levodopa, Carbidopa Monohydrate, the active ingredients in Lecigimon, are a dopamine precursor/COMT inhibitor combination presented as a fixed‑dose oral tablet for intestinal use. It is indicated for the management of Parkinson's disease symptoms in adult patients. GNH USA supplies Lecigimon as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Lecigimon is used within the Parkinson's disease therapeutic pathway to improve motor control and reduce off‑periods. - Parkinson's disease: enhances dopaminergic stimulation to improve tremor, rigidity and bradykinesia. - Parkinson's disease with motor fluctuations: prolongs levodopa plasma half‑life, helping to smooth symptom control. - Advanced Parkinson's disease: provides combined levodopa delivery with peripheral decarboxylase and COMT inhibition to maintain consistent central dopamine levels.

Lecigimon may cause a range of adverse reactions.

Common Side Effects: - Nausea: mild to moderate gastrointestinal upset. - Dizziness: often related to orthostatic changes. - Headache: transient and usually resolves. - Insomnia: difficulty initiating or maintaining sleep. - Orthostatic hypotension: drop in blood pressure upon standing. - Dry mouth: reduced salivation.

Serious or Rare Side Effects: - Severe hypotension: marked blood pressure decline requiring medical attention. - Hallucinations or psychosis: visual or auditory disturbances. - Dyskinesia: involuntary movements due to excess central dopamine. - Hepatic enzyme elevation: abnormal liver function tests. - Neuroleptic malignant syndrome: rare but life‑threatening reaction.

Before initiating Lecigimon, clinicians should consider several safety measures. - Blood pressure monitoring: watch for orthostatic changes, especially after dose adjustments. - Hepatic function assessment: evaluate liver enzymes periodically. - Psychiatric evaluation: monitor for hallucinations or mood alterations. - Renal impairment dosing: adjust dose in patients with reduced kidney function. - Concomitant MAO‑B inhibitors: avoid co‑administration to prevent hypertensive crises. - Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Lecigimon can interact with several medication classes, requiring careful management.

Major Interactions (Avoid): - Non‑selective MAO inhibitors: risk of hypertensive crisis. - Alpha‑adrenergic blockers: may cause severe hypotension. - Antipsychotics (especially dopamine antagonists): can diminish therapeutic effect.

Moderate Interactions (Monitor Closely): - SSRIs and SNRIs: increased risk of serotonin syndrome. - Other dopaminergic agents: may exacerbate dyskinesia. - Diuretics: enhance orthostatic hypotension. - NSAIDs: potential for gastrointestinal irritation when combined with levodopa.